Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection

Journal of Immunological Methods

Volumn 390, Issue 1-2, 2013, Pages 41-51

  Congy Jolivet, Nicolas ^a,b   Drocourt, Daniel ^c   Portet, Sylvain ^a   Tiraby, Gérard ^c   Blancher, Antoine ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU RANGUEIL   (France)

^c Zone industrielle de Montaudran   (France)

Author keywords

Anti HLA antibodies; Chimeric monoclonal antibody; Flow cytometry crossmatch assay; Luminex LABScreen assays; Lymphocytotocicity cross match assay; Threshold of positivity

Indexed keywords

CHIMERIC ANTIBODY; EPITOPE; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ2 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL CELL; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; FLOW CYTOMETRY; GOOD LABORATORY PRACTICE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MEASUREMENT REPEATABILITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPRODUCIBILITY; STANDARDIZATION; VALIDATION PROCESS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CHO CELLS; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; FLOW CYTOMETRY; HLA ANTIGENS; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTES; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; REFERENCE STANDARDS;

EID: 84875246772     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.01.007     Document Type: Article

References (31)

1. Amico P., Hönger G., Mayr M., Steiger J., Hopfer H., Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009, 87:1681.
2. Barnstable C.J., Bodmer W.F., Brown G., Galfre G., Milstein C., Williams A.F., Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens - new tools for genetic analysis. Cell 1978, 14:9.
3. Bromberg J.S., Heeger P.S., Li X.C. Evolving paradigms that determine the fate of an allograft. Am. J. Transplant. 2010, 10:1143.
4. Dechant M., Vidarsson G., Stockmeyer B., Repp R., Glennie M.J., Gramatzki M., van De Winkel J.G., Valerius T. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002, 100:4574.
5. Elsässer D., Valerius T., Repp R., Weiner G.J., Deo Y., Kalden J.R., van de Winkel J.G., Stevenson G.T., Glennie M.J., Gramatzki M. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996, 87:3803.
6. Evans R.L., Faldetta T.J., Humphreys R.E., Pratt D.M., Yunis E.J., Schlossman S.F. Peripheral human T cells sensitized in mixed leukocyte culture synthesize and express Ia-like antigens. J. Exp. Med. 1978, 148:1440.
7. Everly M.J., Everly J.J., Arend L.J., Brailey P., Susskind B., Govil A., Rike A., Roy-Chaudhury P., Mogilishetty G., Alloway R.R., Tevar A., Woodle E.S. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant. 2009, 9:1063.
8. Gebel H.M., Bray R.A., Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am. J. Transplant. 2003, 3:1488.
9. Gloor J.M., Sethi S., Stegall M.D., Park W.D., Moore S.B., DeGoey S., Griffin M.D., Larson T.S., Cosio F.G. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am. J. Transplant. 2007, 7:2124.
10. Guettinger Y., Barbin K., Peipp M., Bruenke J., Dechant M., Horner H., Thierschmidt D., Valerius T., Repp R., Fey G.H., Stockmeyer B. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells. J. Immunol. 2010, 184:1210.
11. Ko H.S., Fu S.M., Winchester R.J., Yu D.T., Kunkel H.G. Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J. Exp. Med. 1979, 150:246.
12. Koka P., Chia D., Terasaki P.I., Chan H., Chia J., Ozawa M., Lim E. The role of IgA anti-HLA class I antibodies in kidney transplant survival. Transplantation 1993, 56:207-211.
13. Lefaucheur C., Loupy A., Hill G.S., Andrade J., Nochy D., Antoine C., Gautreau C., Charron D., Glotz D., Suberbielle-Boissel C. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 2010, 21:1398.
14. Loupy A., Suberbielle-Boissel C., Hill G.S., Lefaucheur C., Anglicheau D., Zuber J., Martinez F., Thervet E., Méjean A., Charron D., Duong van Huyen J.P., Bruneval P., Legendre C., Nochy D. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am. J. Transplant. 2009, 9:2561.
15. Mizutani K., Terasaki P., Hamdani E., Esquenazi V., Rosen A., Miller J., Ozawa M. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am. J. Transplant. 2007, 7:1027-1031.
16. Moreso F., Seron D., O'Valle F., Ibernon M., Gomà M., Hueso M., Cruzado J.M., Bestard O., Duarte V., del Moral R.G., Grinyó J.M. Immunephenotype of glomerular and interstitial infiltrating cells in protocol renal allograft biopsies and histological diagnosis. Am. J. Transplant. 2007, 7:2739.
17. Murphey C.L., Forsthuber T.G. Trends in HLA antibody screening and identification and their role in transplantation. Expert. Rev. Clin. Immunol. 2008, 4:391.
18. Nikaein A., Cherikh W., Nelson K., Baker T., Leffell S., Bow L., Crowe D., Connick K., Head M.A., Kamoun M., Kimball P., Klohe E., Noreen H., Rebellato L., Sell T., Sullivan K., Land G. Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009, 87:557.
19. Patel R., Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 1969, 280:735.
20. Pei R., Wang G., Tarsitani C., Rojo S., Chen T., Takemura S., Liu A., Lee J. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum. Immunol. 1998, 59:313.
21. Pei R., Lee J., Chen T., Rojo S., Terasaki P.I. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum. Immunol. 1999, 60:1293.
22. Pei R., Lee J.H., Shih N.J., Chen M., Terasaki P.I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003, 75:43.
23. Regele H., Böhmig G.A., Habicht A., Gollowitzer D., Schillinger M., Rockenschaub S., Watschinger B., Kerjaschki D., Exner M. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J. Am. Soc. Nephrol. 2002, 13:2371.
24. Robinson J., Halliwell J.A., McWilliam H., Lopez R., Parham P., Marsh S.G. The IMGT/HLA database. Nucleic Acids Res. 2012.
25. Sawitzki B., Pascher A., Babel N., Reinke P., Volk H.D. Can we use biomarkers and functional assays to implement personalized therapies in transplantation?. Transplantation 2009, 87:1595.
26. Scherer A., Gwinner W., Mengel M., Kirsch T., Raulf F., Szustakowski J.D., Hartmann N., Staedtler F., Engel G., Klupp J., Korn A., Kehren J., Haller H. Transcriptome changes in renal allograft protocol biopsies at 3months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6months. Nephrol. Dial. Transplant. 2009, 24:2567.
27. Schwartz A., Gaigalas A.K., Wang L., Marti G.E., Vogt R.F., Fernandez-Repollet E. Formalization of the MESF unit of fluorescence intensity. Cytometry B Clin. Cytom. 2004, 57:1-6.
28. Tambur A.R., Ramon D.S., Kaufman D.B., Friedewald J., Luo X., Ho B., Skaro A., Caicedo J., Ladner D., Baker T., Fryer J., Gallon L., Miller J., Abecassis M.M., Leventhal J. Perception versus reality?: Virtual crossmatch - how to overcome some of the technical and logistic limitations. Am. J. Transplant. 2009, 9:1886.
29. Terasaki P.I. The HLA-matching effect in different cohorts of kidney transplant recipients. Clin. Transpl. 2000, 497.
30. Terasaki P.I., Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am. J. Transplant. 2004, 4:438.
31. Vlad G., Ho E.K., Vasilescu E.R., Colovai A.I., Stokes M.B., Markowitz G.S., D'Agati V.D., Cohen D.J., Ratner L.E., Suciu-Foca N. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum. Immunol. 2009, 70:589.